Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Cancer Insight, LLC
Sponsor:
Collaborators:
Genentech, Inc.
Galena Biopharma, Inc.
Information provided by (Responsible Party):
George E. Peoples, Cancer Insight, LLC
ClinicalTrials.gov Identifier:
NCT01570036
First received: March 25, 2012
Last updated: November 5, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)